|
|
|
| Application effect observation of Roxadustat in the treatment of renal anemia in maintenance hemodialysis |
| KONG Xiangdong XU Jinhua YU Yangjie CHEN Linyan |
| Department of Nephrology, the First People’s Hospital of Fuyang District, Zhejiang Province, Hangzhou 311400, China |
|
|
|
Abstract Objective To observe the efficacy and safety of Roxadustat in the treatment of renal anemia in maintenance hemodialysis (MHD). Methods From August to October 2019, 15 MHD patients with renal anemia treated by the Blood Purification Center of the First People’s Hospital of Fuyang District, Hangzhou City, Zhejiang Province were selected as the study subjects, all of them received exogenous erythropoietin (EPO) treatment. The patient stopped EPO, and the iron agent was stopped at the same time when the iron agent was applied. After one week, the oral Roxadustat treatment was started, with the dose of 100-120 mg/time, three times per week, and the course of treatment was 12 weeks. The changes of hemoglobin, blood lipid (triacylglycerol [TG], total cholesterol [TC], low-density lipoprotein (LDL), high-density lipoprotein [HDL]) and ferritin were detected before and after treatment. Adverse drug reactions during treatment were recorded. Results After treatment, the hemoglobin level and ferritin level were significantly increased and decreased compared with those before treatment, with statistically significant differences (all P ＜ 0.05). After treatment, the TC and LDL levels of the patients were significantly decreased compared with those before treatment, and the differences were statistically significant (all P ＜ 0.05); however, TG and HDL of the patients did not change significantly before and after treatment, and the differences were not statistically significant (P ＞ 0.05). Conclusion Roxadustat can effectively treat renal anemia in MHD patients, which may provide a new treatment method for clinical practice.
|
|
|
|
|
|
[1] Li Y，Shi H，Wang WM，et al. Prevalence，awareness，and treatment of anemia in Chinese patients with nondialysis chronic kidney disease：First multicenter，cross-sectional study [J]. Medicine（Baltimore），2016，95（24）：e3872.
[2] 何琴，蔡宏，张伟明.维持性血液透析患者贫血状况与预后的关系[J].中华肾脏病杂志，2016，32（2）：110-117.
[3] Tanaka T，Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents [J]. Exp Cell Res，2012，318（9）：1068-1073.
[4] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识（2018修订版）[J].中华肾脏病杂志，2018，34（11）：860-866.
[5] Zhang L，Wang F，Wang L，et al. Prevalence of chronic kidney disease in China：a cross-sectional survey [J]. Lancet，2012，379（9818）：815-822.
[6] 张晓华，李静，王利华.近5年维持性血液透析患者的流行病学调查分析[J].中国血液净化，2015，14（11）：698-702.
[7] 李万国，李兰霞，王宏，等.肾康注射液在慢性肾脏病一体化治疗中的疗效观察[J].中国现代医生，2019，57（8）：142-144.
[8] 赵艺欣，李明旭.左卡尼汀辅助治疗对维持性血液透析贫血及脏器功能损伤的影响[J].中国医药导报，2017，14（3）：156-159.
[9] 刘素青.口服HIF稳定剂与静脉补铁治疗肾性贫血的临床观察[J].中国医学创新，2019，16（7）：31-36.
[10] 张慧然，徐金升，白亚玲，等.维持性血液透析患者贫血治疗达标情况及影响因素研究[J].中国全科医学，2016， 19（19）：2284-2288.
[11] 李梅，黄楠，杨春霞，等.影响长期维持性血液透析患者发生肾性贫血的危险因素分析[J].昆明医科大学学报，2019，40（10）：125-130.
[12] 林霞，冯江超.铁调素与肾性贫血相关影响因素的研究进展[J].中国血液净化，2018，17（5）：308-312.
[13] 倪华，彭家清.维持性血液透析患者肾性贫血的相关因素分析[J].临床肾脏病杂志，2017，17（7）：427-430.
[14] 叶蕾，张桂霞，黄扬扬，等.安徽省维持性血液透析患者贫血患病率及血红蛋白达标率的流行病学调查[J].中华肾脏病杂志，2016，32（4）：264-270.
[15] 李璐璐，黄铁花，卫四宝，等.重组人促红细胞生成素不良反应149例文献分析[J].中国药师，2018，21（3）：438-441.
[16] 梁矛锋，简汝堃，刘春花.大剂量促红细胞生成素治疗血液透析患者肾性贫血的效果及对血清铁蛋白、叶酸水平的影响研究[J].中国医药科学，2019，9（5）：70-72.
[17] 陈艳春.维持性血液透析患者血浆铁调素水平变化及临床意义[J].当代医学，2018，24（33）：151-152.
[18] 杨荆，肖桦，樊文星.老年血透患者促红细胞生成素抵抗的影响因素[J].中国老年学杂志，2018，38（24）：6006-6008.
[19] 魏鑫，任野平.肾性贫血与低氧诱导因子[J].中国血液净化，2018，17（1）：6-8.
[20] 郝传明，任玥衡.缺氧诱导因子与慢性肾脏病贫血[J].肾脏病与透析肾移植杂志，2018，27（2）：151-152.
[21] 王睿，胡洪涛，胡双，等.罗沙司他治疗慢性肾脏病贫血患者的Meta分析[J].临床肾脏病杂志，2019，19（12）：871-876.
[22] Besarab A，Chernyavskaya E，Motylev I，et al. Roxadustat （FG-4592）：correction of anemia in incident dialysis patients [J]. J Am Soc Nephrol，2016，27（4）：1225-1233.
[23] Chen N，Hao C，Liu BC，et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis [J]. N Engl J Med，2019，381（11）：1011-1022. |
|
|
|
